Aeluma Names Brendan Moran Vice President of Engineering

Aeluma (NASDAQ: ALMU) appointed Brendan Moran, Ph.D. as Vice President of Engineering, reporting to President and CEO Jonathan Klamkin.

Rhea-AI Summary

Aeluma (NASDAQ: ALMU) appointed Brendan Moran, Ph.D. as Vice President of Engineering, reporting to President and CEO Jonathan Klamkin.

Moran will lead engineering to advance commercialization and manufacturing readiness of Aeluma’s compound semiconductor products for AI infrastructure, mobile, consumer electronics, defense, aerospace, AR/VR, robotics, automotive, and quantum markets.

Argus Jun 23 session

-6.45% close to close 0.6x rel. volume Open Argus

Details

News Market Reaction – ALMU

On Jun 23, the day this news came out, ALMU closed 6.45% below the previous close.

Data tracked by StockTitan Argus for the Jun 23 session.

Key Figures

Portfolio revenue: $300 million annual revenue Industry experience: 18-year career Flagship design-ins: 8 consecutive flagship design-ins +3 more

Portfolio revenue

$300 million annual revenue

Global mobile flash portfolio managed by Brendan Moran at Lumileds

Industry experience

18-year career

Brendan Moran’s tenure at Lumileds before joining Aeluma

Flagship design-ins

8 consecutive flagship design-ins

Secured for a high-profile mobile customer at Lumileds

Team size led

more than 20 engineers and program managers

Global product development organization managed by Moran

Products released

more than 25 products

Innovative products released to high-volume manufacturing

Units shipped

more than four billion units

Total units from products released under Moran’s leadership

Historical Context

5 past events · Latest: May 28

5 events

1. May 28

   quantum update

   24h Move

   -0.3%

   Outlined potential benefits from CHIPS Act quantum incentives and partnerships.

2. May 21

   industry award

   24h Move

   +11.3%

   CEO recognized with prestigious IPRM award for heterogeneous integration work.

3. May 13

   earnings results

   24h Move

   -15.4%

   Reported Q3 results with modest revenue, losses, and narrowed FY26 guidance.

4. May 12

   investor conferences

   24h Move

   +16.2%

   Announced participation in multiple upcoming investor conferences and meetings.

5. Apr 29

   earnings date

   24h Move

   +1.4%

   Set date and call details for upcoming Q3 fiscal 2026 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

compound semiconductor, wearable led phototherapy, clinical trials, 510(k) fda clearance

4 terms

compound semiconductor technical

"commercialization and manufacturing readiness of Aeluma’s compound semiconductor products."

Materials made from two or more chemical elements designed to control how electricity and light behave, used to make electronic and optical components. Like mixing metals to get a stronger alloy, these semiconductors let charges move faster or emit light more efficiently than common silicon, enabling faster wireless signals, efficient power conversion, LEDs and lasers. Investors care because they underpin higher‑growth, higher‑margin markets and depend on specialized manufacturing and supply chains that can affect profitability and valuation.

wearable led phototherapy medical

"developing a wearable LED phototherapy platform and taking it through clinical trials"

Wearable LED phototherapy is a small device you can wear on the body that uses colored light from LEDs to stimulate biological processes in skin or underlying tissue for therapeutic or cosmetic purposes. Investors should care because these devices combine health treatment with consumer-friendly form factors, creating opportunities for recurring sales, subscription services, regulatory clearance or clinical validation, and scale in both medical and direct-to-consumer markets—think of it as a light-based treatment you can take with you like a wearable appliance.

clinical trials medical

"wearable LED phototherapy platform and taking it through clinical trials and 510(k) FDA clearance."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

510(k) fda clearance regulatory

"taking it through clinical trials and 510(k) FDA clearance."

A 510(k) FDA clearance is an official finding that a medical device is sufficiently similar to an already approved device so it can be legally marketed in the U.S. Think of it like showing a new gadget works like an existing, trusted model rather than proving an entirely new design. For investors, 510(k) clearance typically means faster market access and lower regulatory risk than full approval, which can affect revenue timelines and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Key Appointment to Drive Product Development and Commercialization Across Growing Markets

GOLETA, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Aeluma, Inc. (NASDAQ: ALMU), a semiconductor company specializing in high-performance, scalable technologies for mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum, announced today it has appointed Brendan Moran, Ph.D. as its Vice President of Engineering. Dr. Moran will drive the commercialization and manufacturing readiness of Aeluma’s compound semiconductor products.

Dr. Moran joins Aeluma following a distinguished 18-year career at Lumileds, where he most recently served as Senior Director of R&D, and previously as Senior Director of Product Development. During his tenure at Lumileds, Dr. Moran managed the product strategy and full-cycle development for a global mobile flash portfolio that generated more than $300 million in annual revenue and captured eight consecutive flagship design-ins for a high-profile customer. He led a global product development organization of more than 20 engineers and program managers and orchestrated the release of more than 25 innovative products to high-volume manufacturing that totaled more than four billion units. Dr. Moran also served as Principal Engineer at Allux Medical earlier in his career, developing a wearable LED phototherapy platform and taking it through clinical trials and 510(k) FDA clearance.

At Aeluma, Dr. Moran will lead the engineering organization as the company transitions its promising technologies into market-ready products for AI infrastructure, mobile and consumer electronics, defense and aerospace, and quantum.

“We are excited to welcome Brendan to the Aeluma team,” said Jonathan Klamkin, Ph.D., President and CEO. “His experience with scaling semiconductor photonics for consumer markets comes at a pivotal time with commercial traction growing across our target markets. Brendan’s proven leadership will help accelerate our transition to commercial-scale manufacturing and broad market product introduction.”

Dr. Moran commented, “The versatility of Aeluma’s scalable heterogeneous integration platform presents a massive opportunity to meet the current high customer demand for compound semiconductor devices in the communications and sensing markets. At this exciting time for Aeluma, I am very pleased to join and help drive the next stage of growth.”

Dr. Moran holds a Ph.D. in Materials from the University of California Santa Barbara. He will report directly to President and CEO Dr. Jonathan Klamkin.

About Aeluma

Aeluma (NASDAQ: ALMU) is a transformative semiconductor company specializing in high-performance photonic and electronic technologies that scale. The company’s proprietary platform combines compound semiconductors with scalable manufacturing used for mass market microelectronics to enable volume production and large-scale integration. Applications for Aeluma’s technology include mobile, AI, defense and aerospace, robotics, automotive, AR/VR, and quantum. Headquartered in Goleta, California, Aeluma operates state-of-the-art R&D and manufacturing capabilities for semiconductor wafer production, quick-turn chip fabrication, rapid prototyping, test and validation. Aeluma also partners with production-scale fabrication foundries, packaging, and integration companies. For more information, visit www.aeluma.com.

Company:
Aeluma, Inc.
(805) 351-2707
info@aeluma.com

Investor Contact:
Financial Profiles, Inc.
Moira Conlon and Alex Villalta
(310) 622-8227
ir@aeluma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Brendan Moran and what is his new role at Aeluma (NASDAQ: ALMU)?

Brendan Moran, Ph.D., has been named Vice President of Engineering at Aeluma. According to Aeluma, he will lead the engineering organization, focusing on commercialization and manufacturing readiness of the company’s compound semiconductor products across multiple high-growth end markets.

What experience does Brendan Moran bring to Aeluma (ALMU) as Vice President of Engineering?

Brendan Moran brings over 18 years of semiconductor and photonics experience. According to Aeluma, he previously served as Senior Director of R&D and Product Development at Lumileds, overseeing a global mobile flash portfolio generating more than $300 million in annual revenue.

How will Brendan Moran’s appointment impact Aeluma’s product commercialization strategy?

Aeluma indicates that Brendan Moran will drive commercialization and manufacturing readiness for its compound semiconductor products. His role includes transitioning Aeluma’s scalable heterogeneous integration platform from promising technologies into market-ready products for AI infrastructure, mobile, consumer electronics, defense, aerospace, and quantum applications.

What markets is Aeluma (NASDAQ: ALMU) targeting with its compound semiconductor products?

According to Aeluma, its compound semiconductor technologies address AI infrastructure, mobile and consumer electronics, defense and aerospace, robotics, automotive, AR/VR, and quantum markets. Brendan Moran’s leadership is expected to support moving these technologies into high-volume, market-ready products for communications and sensing applications.

What prior commercialization successes has Brendan Moran achieved before joining Aeluma (ALMU)?

At Lumileds, Brendan Moran managed a global mobile flash portfolio generating over $300 million annually. According to Aeluma, he led releases of more than 25 products into high-volume manufacturing, totaling over four billion units and securing eight consecutive flagship design-ins for a major customer.

What is Brendan Moran’s background in clinical and regulatory development relevant to Aeluma?

Earlier in his career, Brendan Moran served as Principal Engineer at Allux Medical. According to Aeluma, he developed a wearable LED phototherapy platform and advanced it through clinical trials and 510(k) FDA clearance, adding medical device and regulatory experience to his semiconductor background.